| 发明名称 |
Anti-C5a antibodies |
| 摘要 |
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease. |
| 申请公布号 |
US9371378(B1) |
申请公布日期 |
2016.06.21 |
| 申请号 |
US201615040258 |
申请日期 |
2016.02.10 |
| 申请人 |
Alexion Pharmaceuticals, Inc. |
发明人 |
Rother Russell P.;Sheridan Douglas L.;Tamburini Paul P.;Zhang Yuchun |
| 分类号 |
C07K16/28;A61K39/395;C07K16/18;A61K39/00 |
主分类号 |
C07K16/28 |
| 代理机构 |
|
代理人 |
Rahemba, Esq. Tara;Remillard, Esq. Jane E.;Sloper, Esq. Jill Gorny |
| 主权项 |
1. An isolated antibody, or antigen-binding fragment thereof, that binds C5a, wherein the antibody, or antigen-binding fragment thereof, comprises complementarity determining regions (CDRs) of a heavy chain variable region comprising the amino acid sequence depicted in SEQ ID NO: 45 and CDRs of a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO: 42. |
| 地址 |
New Haven CT US |
